Alpine Immune Sciences Inc Revenue Growth Rates (ALPN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Alpine Immune Sciences Inc   (NASDAQ: ALPN)
 

ALPN's Revenue Growth by Quarter and Year

Alpine Immune Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALPN Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 7.03
FY 7.03

ALPNs Annual Revenue
Alpine Immune Sciences Inc 's Revenue in the fiscal year 2023 $ 58.88 millions
Alpine Immune Sciences Inc 's Revenue in the fiscal year 2022 $ 30.06 millions
Alpine Immune Sciences Inc 's Revenue in the fiscal year 2021 $ 23.44 millions
Alpine Immune Sciences Inc 's Revenue in the fiscal year 2020 $ 9.34 millions
Alpine Immune Sciences Inc 's Revenue in the fiscal year 2019 $ 1.74 millions




ALPN Revenue first quarter 2024 Y/Y Growth Comment
Alpine Immune Sciences Inc reported fall in Revenue in the first quarter 2024 by -25.11% to $ 7.03 millions, from the same quarter in 2023.
The drop in the first quarter 2024 Alpine Immune Sciences Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 196.42%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 189 other companies have achieved higher Revenue growth. While Alpine Immune Sciences Inc ' s Revenue drop of -25.11% ranks overall at the positon no. 3455 in the first quarter 2024.


ALPN Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 1009.71 % -37.1 % -21.63 %
3rd Quarter September - 19.95 % -1.76 % 343.75 %
2nd Quarter June - 62.38 % -26.93 % 949.28 %
1st Quarter March -25.11 % -31.11 % 316.82 % 200 %
FY   - 95.78 % 28.23 % -

Financial Statements
Alpine Immune Sciences Inc 's first quarter 2024 Revenue $ 7.03 millions ALPN's Income Statement
Alpine Immune Sciences Inc 's first quarter 2023 Revenue $ 9.39 millions Quarterly ALPN's Income Statement


ALPN Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 207.27 % -66.79 % -48.12 %
3rd Quarter September - 16.88 % 58.22 % 17.68 %
2nd Quarter June - -8.52 % -61.19 % 121.41 %
1st Quarter March -77.21 % 237.77 % 208.37 % -42.02 %
FY (Year on Year)   - 95.78 % 28.23 % -


Back to ALPN Growth rate Comparisons >> Back to ALPN Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #190
Healthcare Sector #513
Overall #3455

Revenue Y/Y Growth Statistics
High Average Low
1011.42 % 196.42 % -100 %
(Dec 31 2023)   (Mar 31 2019)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #190
Healthcare Sector #513
Overall #3455
Revenue Y/Y Growth Statistics
High Average Low
1011.42 % 196.42 % -100 %
(Dec 31 2023)   (Mar 31 2019)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Alpine Immune Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
238.15 % 47.81 % -100 %
(Mar 31 2023)  


ALPN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Alpine Immune Sciences Inc disclosed fall in Revenue from the fourth quarter by -77.21% to $ 7.03 millions, from $ 30.85 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2024 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 199 other companies have achieved higher Revenue quarter on quarter growth. While Alpine Immune Sciences Inc 's Revenue growth quarter on quarter, overall rank is 3566.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #200
Healthcare Sector #532
Overall #3566
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #200
Healthcare Sector #532
Overall #3566
Revenue Q/Q Growth Statistics
High Average Low
238.15 % 47.81 % -100 %
(Mar 31 2023)  


ALPN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Alpine Immune Sciences Inc disclosed fall in Revenue from the fourth quarter by -77.21% to $ 7.03 millions, from $ 30.85 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2024 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 199 other companies have achieved higher Revenue quarter on quarter growth. While Alpine Immune Sciences Inc 's Revenue growth quarter on quarter, overall rank is 3566.


Alpine Immune Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 56.52 $ 58.88 $ 30.80 $ 29.12 $ 25.82
Y / Y Revenue Growth (TTM) 118.89 % 95.84 % -2.85 % -8.57 % -23.61 %
Year on Year Revenue Growth Overall Ranking # 3271 # 303 # 511 # 345 # 128
Seqeuential Revenue Change (TTM) -4 % 91.16 % 5.75 % 12.78 % -14.11 %
Seq. Revenue Growth (TTM) Overall Ranking # 2969 # 1743 # 1924 # 2814 # 530


Cumulative Revenue growth Comment
Although Alpine Immune Sciences Inc 's Annual Revenue growth year on year were below company's average 147.22% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 118.89% year on year, from 95.84% in Dec 31 2023.

In the Healthcare sector 469 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 303 to 3271.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 164
Healthcare Sector # 470
Overall # 3271

Revenue TTM Y/Y Growth Statistics
High Average Low
512.03 %
 147.22 %
-23.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 164
Sector # 442
S&P 500 # 2969
Cumulative Revenue growth Comment
Although Alpine Immune Sciences Inc 's Annual Revenue growth year on year were below company's average 147.22% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 118.89% year on year, from 95.84% in Dec 31 2023.

In the Healthcare sector 469 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 303 to 3271.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 164
Healthcare Sector # 470
Overall # 3271

Revenue TTM Y/Y Growth Statistics
High Average Low
512.03 %
147.22 %
-23.61 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 164
Sector # 442
S&P 500 # 2969




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALPN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical Inc -0.21%$ -0.215 millions
Mettler toledo International Inc -0.30%$ -0.300 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
3m Company-0.64%$ -0.644 millions
Orgenesis Inc -0.70%$ -0.704 millions
T2 Biosystems Inc -0.82%$ -0.818 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Enhabit Inc -1.02%$ -1.018 millions
Valneva Se-1.11%$ -1.112 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Zimvie Inc -1.84%$ -1.836 millions
Sight Sciences Inc -1.87%$ -1.870 millions
Opus Genetics Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Wave Life Sciences Ltd -3.02%$ -3.024 millions
Fulgent Genetics Inc -3.12%$ -3.119 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions


About Alpine Immune Sciences Inc Revenue Growth Rates (ALPN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Alpine Immune Sciences Inc (CIK 1626199).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001626199-24-000064
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Alpine Immune Sciences Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.